EP2869821A2 - Zusammensetzungen und verfahren zur behandlung und hemmung von virusinfektionen - Google Patents
Zusammensetzungen und verfahren zur behandlung und hemmung von virusinfektionenInfo
- Publication number
- EP2869821A2 EP2869821A2 EP13813787.2A EP13813787A EP2869821A2 EP 2869821 A2 EP2869821 A2 EP 2869821A2 EP 13813787 A EP13813787 A EP 13813787A EP 2869821 A2 EP2869821 A2 EP 2869821A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- warts
- pharmaceutically acceptable
- treatment
- hydroxychloroquine
- amodiaquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 title claims abstract description 76
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 18
- 208000036142 Viral infection Diseases 0.000 title description 3
- 230000009385 viral infection Effects 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 72
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 229960004171 hydroxychloroquine Drugs 0.000 claims abstract description 55
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims abstract description 55
- 229960001444 amodiaquine Drugs 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 43
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims abstract description 39
- 229960003677 chloroquine Drugs 0.000 claims abstract description 39
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 241000282414 Homo sapiens Species 0.000 claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 230000010076 replication Effects 0.000 claims abstract description 15
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 14
- 230000009841 epithelial lesion Effects 0.000 claims abstract description 9
- 201000010153 skin papilloma Diseases 0.000 claims description 171
- 208000000260 Warts Diseases 0.000 claims description 160
- 241000700605 Viruses Species 0.000 claims description 27
- 241000701806 Human papillomavirus Species 0.000 claims description 22
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010059313 Anogenital warts Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 7
- 201000004201 anogenital venereal wart Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 26
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000000241 respiratory effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 78
- 239000007921 spray Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 229940079593 drug Drugs 0.000 description 29
- 239000003814 drug Substances 0.000 description 29
- 235000019441 ethanol Nutrition 0.000 description 21
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 229960004194 lidocaine Drugs 0.000 description 17
- 235000016257 Mentha pulegium Nutrition 0.000 description 15
- 235000004357 Mentha x piperita Nutrition 0.000 description 15
- 230000008034 disappearance Effects 0.000 description 15
- 235000001050 hortel pimenta Nutrition 0.000 description 15
- 239000002674 ointment Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 10
- 235000015110 jellies Nutrition 0.000 description 10
- 239000008274 jelly Substances 0.000 description 10
- 229960000992 amodiaquine hydrochloride Drugs 0.000 description 9
- 208000032544 Cicatrix Diseases 0.000 description 8
- 244000246386 Mentha pulegium Species 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 229960002328 chloroquine phosphate Drugs 0.000 description 8
- 210000004392 genitalia Anatomy 0.000 description 8
- 210000003127 knee Anatomy 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 231100000241 scar Toxicity 0.000 description 8
- 230000037387 scars Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 7
- 241001479543 Mentha x piperita Species 0.000 description 7
- 230000003796 beauty Effects 0.000 description 7
- 210000001513 elbow Anatomy 0.000 description 7
- 210000003811 finger Anatomy 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 210000004872 soft tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- JCBIVZZPXRZKTI-UHFFFAOYSA-N 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol;sulfuric acid Chemical compound OS(O)(=O)=O.ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 JCBIVZZPXRZKTI-UHFFFAOYSA-N 0.000 description 6
- 208000000907 Condylomata Acuminata Diseases 0.000 description 6
- 241000722343 Human papillomavirus types Species 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 230000037390 scarring Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- -1 irdocaine Chemical compound 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229960000724 cidofovir Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000260 male genitalia Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- QKICWELGRMTQCR-UHFFFAOYSA-N 4-[(7-chloroquinolin-4-yl)azaniumyl]pentyl-diethylazanium;dihydrogen phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 QKICWELGRMTQCR-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940089602 epinephrine injection Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000021145 human papilloma virus infection Diseases 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/540,749 US20140011837A1 (en) | 2012-07-03 | 2012-07-03 | Compositions and methods for treating warts associated with viral infections |
| US13/687,273 US20140011838A1 (en) | 2012-07-03 | 2012-11-28 | Compositions and methods for treating warts associated with viral infections |
| US13/932,445 US20140011839A1 (en) | 2012-07-03 | 2013-07-01 | Compositions and methods for treating and inhibiting viral infections |
| PCT/US2013/049046 WO2014008248A2 (en) | 2012-07-03 | 2013-07-02 | Compositions and methods for treating and inhibiting viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2869821A2 true EP2869821A2 (de) | 2015-05-13 |
| EP2869821A4 EP2869821A4 (de) | 2016-04-06 |
Family
ID=49882589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13813787.2A Withdrawn EP2869821A4 (de) | 2012-07-03 | 2013-07-02 | Zusammensetzungen und verfahren zur behandlung und hemmung von virusinfektionen |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2869821A4 (de) |
| CN (1) | CN104703601A (de) |
| CA (1) | CA2927146A1 (de) |
| WO (1) | WO2014008248A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2544153B1 (es) | 2014-02-24 | 2016-06-06 | Ntd Labs, S.L. | Uso de un hidrolizado de caseína como agente antiviral |
| CN104352495A (zh) * | 2014-11-15 | 2015-02-18 | 广州凯普生物科技有限公司 | 一种治疗疣类疾病的药物 |
| US11571416B2 (en) * | 2017-04-13 | 2023-02-07 | Kagoshima University | Amodiaquine analogs and methods of uses thereof |
| CN112955167A (zh) * | 2018-08-06 | 2021-06-11 | 尼尔森生物科学公司 | 疣的治疗 |
| CN109288816B (zh) | 2018-12-04 | 2019-11-22 | 广州凯普医药科技有限公司 | 一种氯喹凝胶及其制备方法和应用 |
| CN110917196B (zh) * | 2020-02-05 | 2020-06-05 | 广州康健医学科技有限公司 | 一种氯喹抑菌消毒液及其应用 |
| CN112089841A (zh) * | 2020-04-05 | 2020-12-18 | 徐静 | 用于治疗上皮组织病毒感染所致疾病的药物组合物 |
| CN114848642A (zh) * | 2022-07-07 | 2022-08-05 | 广州康健医学科技有限公司 | 磷酸氯喹在制备防治高危型hpv感染及宫颈癌前病变与宫颈癌的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0101716A3 (en) * | 1998-04-14 | 2003-01-28 | Jomaa Hassan | Use of organo phosphonic and phosphinic acid derivatives for producing medicaments useful for therapeutic and preventative treatment of infections |
| EP2581081A3 (de) * | 2007-06-01 | 2013-07-31 | The Trustees Of Princeton University | Behandlung von Virusinfektionen durch Modulation von Hostzellen-Stoffwechselpfaden |
-
2013
- 2013-07-02 CN CN201380045847.5A patent/CN104703601A/zh active Pending
- 2013-07-02 WO PCT/US2013/049046 patent/WO2014008248A2/en active Application Filing
- 2013-07-02 EP EP13813787.2A patent/EP2869821A4/de not_active Withdrawn
- 2013-07-02 CA CA2927146A patent/CA2927146A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104703601A (zh) | 2015-06-10 |
| CA2927146A1 (en) | 2014-01-09 |
| WO2014008248A3 (en) | 2014-02-27 |
| WO2014008248A2 (en) | 2014-01-09 |
| EP2869821A4 (de) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014008248A2 (en) | Compositions and methods for treating and inhibiting viral infections | |
| ES2290120T3 (es) | Procedimientos para mejorar la dimension y el aspecto de una herida. | |
| NZ305095A (en) | Water-based topical cream containing nitroglycerin, use in treating sexual dysfunction | |
| JP6359217B2 (ja) | 新規ヨードフォア組成物および使用方法 | |
| US6407125B1 (en) | Pharmacological agent and method of treatment | |
| JPH06100446A (ja) | （Ｓ）−α−フルオロメチル−ヒスチジン及びそのエステルを使用するぜん息の治療方法 | |
| US20060074063A1 (en) | Pharmacological agent and method of treatment | |
| US20140011838A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| US20140011839A1 (en) | Compositions and methods for treating and inhibiting viral infections | |
| AU781066B2 (en) | Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof | |
| US20170296530A1 (en) | Compositions and Methods for Treating and Inhibiting Viral Infections | |
| US4469702A (en) | Analgesic composition and use thereof to ameliorate deep and intractable pain | |
| Miller et al. | Human papillomavirus infection: treatment options for warts. | |
| CA2766630A1 (en) | Anti-wart pharmaceutical composition and method for treating wart | |
| US9144612B2 (en) | Dermatological compositions containing an association of peroxide lipids and zinc, and uses thereof in particular in the treatment of labial and/or genital herpes | |
| US20140011837A1 (en) | Compositions and methods for treating warts associated with viral infections | |
| US9770448B1 (en) | Compositions and methods for treatment of Bowen's disease and related diseases | |
| AU2010263478A1 (en) | Injectable composition containing hydroxychloroquine for local administration for treating hemorrhoids | |
| de Bengoa Vallejo et al. | Application of cantharidin and podophyllotoxin for the treatment of plantar warts | |
| US6441009B1 (en) | Agent and method of preventing and treating heavy metal exposure and toxicity | |
| EP3687541A1 (de) | Zusammensetzungen und verfahren zur behandlung von morbus bowen und verwandten krankheiten | |
| Falkland | Disease management: The diagnosis and management of warts | |
| KR101671484B1 (ko) | 오셀타미비르(Oseltamivir)를 포함하는 인유두종 바이러스 치료용 약학적 조성물 | |
| Adıyaman et al. | Verruca vulgaris and acupuncture: A case report and literature review | |
| RU2595832C9 (ru) | Способ достижения длительной клинической ремиссии хронической впч-инфекции, проявляющейся остроконечными кондиломами аногенитальной области |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150127 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20160304 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/20 20060101ALI20160229BHEP Ipc: A61K 31/4706 20060101AFI20160229BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GRACELAND BIOTECHNOLOGY CATALYST, LLC Owner name: OBI, JUSTICE E. |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180201 |